Mounjaro vs Yurpeak in India — molecule, dose, price

Mounjaro vs Yurpeak: a structural comparison

This page is a structural comparison of two tirzepatide brands available in India — Mounjaro (Eli Lilly) and Yurpeak (Cipla). It is not a prescription and not a recommendation for any individual. Both products use the same active molecule (tirzepatide), so the meaningful differences lie in manufacturer, brand presence across Indian pharmacy networks, and pricing.

If you have landed here because your doctor mentioned one or the other, or because you are comparing options on Tata 1mg, Apollo, Pharmeasy, or Netmeds, the sections below lay out what overlaps and what differs. For current Indian price ranges across pen strengths, see /price. For titration schedules that apply to either brand, see [/tools/titration]. To check availability in your city or pincode, see [/check].

Neutral framing throughout: we describe structure, not suitability. Suitability is a conversation between you and your prescriber.

What is the same

At the molecule level, Mounjaro and Yurpeak are structurally identical: both deliver tirzepatide, a dual GIP/GLP-1 receptor agonist. Because the active ingredient is the same, the following overlap:

• Mechanism of action. Both act on the same receptor pathways, as the label states.
• Dosing cadence. Both are once-weekly subcutaneous injections.
• Titration ladder. Both follow the standard tirzepatide titration — typically starting at 2.5mg and stepping up roughly every four weeks as tolerated. See [/tools/titration] for the structural schedule.
• Side-effect profile. Commonly reported effects — nausea, reduced appetite, constipation, occasional reflux — are described similarly for both brands. See [/guides/tirzepatide-side-effects] for a fuller list.
• Available dose strengths in India. Both are CDSCO-approved across 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg.
• Storage requirements. Refrigeration as per the label.

In short, from a pharmacological standpoint, switching between these two brands is a brand swap, not a molecule swap.

What is different

The meaningful differences are commercial and logistical, not pharmacological.

• Manufacturer. Mounjaro is the originator brand from Eli Lilly, the company that developed tirzepatide. Yurpeak is Cipla's Indian tirzepatide brand, launched as a domestically manufactured option. See [/brands/mounjaro] and [/brands/yurpeak] for individual brand pages.
• Pricing in India. Indian price points differ between the two brands and shift periodically across aggregators like Tata 1mg, Apollo, Pharmeasy, and Netmeds. Yurpeak, as a Cipla-manufactured product, is generally positioned at a different price tier than Mounjaro. For up-to-date ₹ ranges across strengths, always check /price rather than relying on a static figure.
• Pharmacy availability. Mounjaro has had a longer presence in Indian pharmacy networks and is more broadly stocked in metros. Yurpeak's distribution is expanding but may be uneven across tier-2 and tier-3 cities. Use [/check] to see current availability by pincode.
• Pen design and packaging. The injector device, packaging, and labelling differ between the two manufacturers, even though the drug inside is the same.
• Brand recognition. Mounjaro is the globally recognised originator name; Yurpeak is an India-specific brand. This sometimes matters for patients travelling abroad who need refills.

None of these differences change the underlying molecule or how it works in the body.

Questions to bring to your doctor

If you are weighing Mounjaro against Yurpeak, these prompts may help structure the conversation:

• "Both are tirzepatide — is there a clinical reason to prefer one brand over the other for me?"
• "What is the current ₹ price difference at the strength you are considering, and how does that affect long-term affordability?"
• "Which brand is reliably stocked at my regular pharmacist or on Tata 1mg / Apollo / Pharmeasy / Netmeds?"
• "If I start on one brand, can I switch to the other later without changing my titration?"
• "Are there any patient-support or cold-chain delivery differences I should know about?"

These are structural questions — your prescriber will weigh them against your medical history. Please consult your doctor before starting, switching, or stopping either brand.